GlassScriptPhysician profile
Ubair Ahmed
NPI 1386840726
$10,080.31
in general payments reported to CMS, 2019-2025
35 companies · $2,334 in 2025
The $2,334 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $228 · 2021: $404 · 2022: $1,027 · 2023: $655 · 2024: $4,608 · 2025: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Food and Beverage: $2,109 · Travel and Lodging: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Food and Beverage | $2,109.24 |
| Travel and Lodging | $987.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,787.11 | 2022-2025 | |
| Glaxosmithkline, LLC. | $852.03 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.77 | 2019-2025 | Ofev |
| Electromed, INC. | $340.24 | 2019-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $242.68 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Jazz Pharmaceuticals INC. | $229.23 | 2019-2025 | |
| Insmed, INC. | $225.66 | 2020-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $213.29 | 2019-2024 | Opsumit, Uptravi |
| Grifols USA, LLC | $193.37 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $187.86 | 2019-2025 | Polivy |
| Baxter Healthcare | $156.41 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $151.73 | 2022-2025 | Tezspire |
| Abiomed | $140.27 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $128.75 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $125.91 | 2019-2024 | Yupelri |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $119.09 | 2019-2025 | |
| Harmony Biosciences LLC | $73.05 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $57.12 | 2019 | |
| Daiichi Sankyo INC. | $51.65 | 2025 | Datroway |
| Advanced Respiratory, INC | $43.30 | 2021 | |
| Novartis Pharmaceuticals Corporation | $40.10 | 2023-2024 | |
| Acacia Pharma INC | $38.13 | 2021-2022 | |
| Viatris Specialty LLC | $37.72 | 2025 | Yupelri |
| United Therapeutics Corporation | $34.85 | 2021-2022 | |
| Caris Mpi, INC. | $29.02 | 2025 | Mi Cancer Seek |
| Pulmonx Corporation | $25.16 | 2019 | |
| Phadia US INC. | $23.64 | 2024 | Immunocap |
| Inspire Medical Systems, INC. | $22.82 | 2025 | Inspire |
| Sunovion Pharmaceuticals INC. | $22.41 | 2019 | |
| Philips North America LLC | $18.97 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.86 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $16.07 | 2024 | Lumryz |
| Gilead Sciences, INC. | $15.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.18 | 2023 | Glassia |
| Apria Healthcare LLC | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ubair Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.